Ceribell Inc (CBLL) Stock Forecast & Price Target

CeriBell is viewed favorably because it pairs a first-mover, AI-enabled rapid EEG platform with strong clinical differentiation, including the first on-label Clarity indication for electrographic status epilepticus and recent expansion into pediatrics and neonates. Commercial traction is already evident in Q2, with revenue of $28.1M, 33% y/y growth, 32 net new accounts for 712 total, and gross margin of 92.3% supported by manufacturing efficiencies and the Vietnam production line, while management targets cash-flow breakeven with cash on hand. The outlook is further strengthened by multiple TAM-expanding catalysts, including delirium commercialization in 4Q26 with a $2,171 NTAP effective October 1, 2026, plus new AI enhancements and next-gen hardware, which should sustain utilization, recurring revenue, and operating leverage.

CeriBell is exposed to material fundamental risk because its hardware supply chain could be pressured by higher tariffs on imports from China or even a ban on Chinese imports, which would likely reduce gross margins and force more sourcing from Vietnam. Although survey data points to strong usage growth for the Ceribell EEG System, including an expected ~30% CAGR between 2025 and 2028 and 41% y/y growth in 2026, the outlook still depends on winning new accounts and sustaining utilization at existing sites. Its valuation support is challenged by execution and regulatory uncertainty, since competition, R&D spending, and future regulatory decisions could slow the company’s ability to convert rapid adoption into durable profitability.